Moderna begins study of COVID-19 vaccine in young children

Moderna announced Tuesday it has started dosing the first participants in a study of its COVID-19 vaccine in young children. The company is studying its coronavirus vaccine in children between the ages of 6 months and 11 years old, and it said Tuesday that the first participants in this phase 2/3 study have been dosed, per The Wall Street Journal. Moderna is expecting to enroll 6,750 healthy participants under 12 years old in the United States and Canada for the study, which is being conducted i...